NL301208I2 - capmatinib of een farmaceutisch aanvaardbaar zout daarvan - Google Patents

capmatinib of een farmaceutisch aanvaardbaar zout daarvan

Info

Publication number
NL301208I2
NL301208I2 NL301208C NL301208C NL301208I2 NL 301208 I2 NL301208 I2 NL 301208I2 NL 301208 C NL301208 C NL 301208C NL 301208 C NL301208 C NL 301208C NL 301208 I2 NL301208 I2 NL 301208I2
Authority
NL
Netherlands
Prior art keywords
capmatinib
pharmaceutically acceptable
acceptable salt
salt
pharmaceutically
Prior art date
Application number
NL301208C
Other languages
English (en)
Dutch (nl)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301208(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NL301208I2 publication Critical patent/NL301208I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NL301208C 2014-07-25 2022-12-16 capmatinib of een farmaceutisch aanvaardbaar zout daarvan NL301208I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25
PCT/IB2015/055561 WO2016012963A1 (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Publications (1)

Publication Number Publication Date
NL301208I2 true NL301208I2 (nl) 2025-03-20

Family

ID=53762251

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301208C NL301208I2 (nl) 2014-07-25 2022-12-16 capmatinib of een farmaceutisch aanvaardbaar zout daarvan

Country Status (31)

Country Link
US (5) US10085993B2 (enExample)
EP (2) EP3848376A1 (enExample)
JP (3) JP6770946B2 (enExample)
KR (2) KR20230136693A (enExample)
CN (2) CN115364061A (enExample)
AR (1) AR101286A1 (enExample)
AU (4) AU2015293539A1 (enExample)
CA (1) CA2954840A1 (enExample)
CL (1) CL2017000180A1 (enExample)
CO (1) CO2017000586A2 (enExample)
DK (1) DK3172209T3 (enExample)
EA (2) EA039220B1 (enExample)
EC (1) ECSP17011672A (enExample)
ES (1) ES2857523T3 (enExample)
FR (1) FR22C1058I2 (enExample)
GT (1) GT201700007A (enExample)
HU (2) HUE053346T2 (enExample)
IL (1) IL250166B (enExample)
JO (1) JO3618B1 (enExample)
MX (2) MX379279B (enExample)
MY (1) MY187276A (enExample)
NL (1) NL301208I2 (enExample)
NO (1) NO2022058I1 (enExample)
PE (1) PE20170523A1 (enExample)
PH (1) PH12017500121A1 (enExample)
PL (1) PL3172209T3 (enExample)
PT (1) PT3172209T (enExample)
SG (2) SG11201700147SA (enExample)
SI (1) SI3172209T1 (enExample)
TW (2) TW202200148A (enExample)
WO (1) WO2016012963A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
DK3172209T3 (da) 2014-07-25 2021-02-22 Novartis Ag Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid
TWI736660B (zh) 2016-08-10 2021-08-21 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
US11407735B2 (en) 2019-05-16 2022-08-09 Novartis Ag Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
JP7675071B2 (ja) * 2019-10-24 2025-05-12 ハンミ ファーマシューティカル カンパニー リミテッド がん細胞の成長を阻害するアミド誘導体を含む医薬調製物およびそれを含有する医薬品
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114853762A (zh) * 2021-02-03 2022-08-05 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AU2023324893A1 (en) * 2022-08-19 2025-03-13 Mirati Therapeutics, Inc. Adagrasib solid pharmaceutical compositions
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
PL2497470T3 (pl) 2006-11-22 2016-04-29 Incyte Holdings Corp Imidazotriazyny i imidazopirymidyny jako inhibitory kinazy
JP6022158B2 (ja) 2008-05-21 2016-11-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ２−フルオロ−Ｎ−メチル−４−［７−（キノリン−６−イル−メチル）−イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの塩及びそれを調製することに関する方法
PT4066821T (pt) * 2009-11-09 2025-06-03 Wyeth Llc Formulações de comprimidos de maleato de neratinib
JP5846647B2 (ja) 2010-02-25 2016-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アピキサバン製剤
NZ603686A (en) * 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
WO2012006298A2 (en) 2010-07-06 2012-01-12 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes
RU2705095C2 (ru) 2012-08-16 2019-11-05 Новартис Аг Комбинация ингибитора pik3 и ингибитора с-мет
DK3172209T3 (da) 2014-07-25 2021-02-22 Novartis Ag Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid

Also Published As

Publication number Publication date
MY187276A (en) 2021-09-17
US10596178B2 (en) 2020-03-24
FR22C1058I1 (fr) 2023-01-06
CL2017000180A1 (es) 2017-09-15
KR20170039211A (ko) 2017-04-10
EA201790259A1 (ru) 2017-06-30
ECSP17011672A (es) 2018-03-31
SG11201700147SA (en) 2017-02-27
AU2021202500A1 (en) 2021-05-20
US20210113569A1 (en) 2021-04-22
IL250166A0 (en) 2017-03-30
CA2954840A1 (en) 2016-01-28
DK3172209T3 (da) 2021-02-22
EA039220B1 (ru) 2021-12-20
EA202191301A1 (ru) 2021-11-30
BR112017000953A2 (pt) 2017-11-14
US20190015418A1 (en) 2019-01-17
SG10201900648SA (en) 2019-02-27
AU2018207947A1 (en) 2018-08-09
JP2017521469A (ja) 2017-08-03
SI3172209T1 (sl) 2021-03-31
CO2017000586A2 (es) 2017-06-20
KR102581121B1 (ko) 2023-09-21
CN115364061A (zh) 2022-11-22
PH12017500121A1 (en) 2017-05-29
AR101286A1 (es) 2016-12-07
NZ728089A (en) 2024-01-26
AU2015293539A1 (en) 2017-02-02
MX2017001177A (es) 2017-05-01
JP2020114852A (ja) 2020-07-30
US20250339440A1 (en) 2025-11-06
AU2020200912B2 (en) 2021-01-28
CN106714784A (zh) 2017-05-24
JP7002587B2 (ja) 2022-01-20
MX2021000595A (es) 2021-04-13
HUS2200054I1 (hu) 2023-01-28
ES2857523T3 (es) 2021-09-29
US20220249498A1 (en) 2022-08-11
WO2016012963A1 (en) 2016-01-28
HUE053346T2 (hu) 2021-06-28
JP6770946B2 (ja) 2020-10-21
PL3172209T3 (pl) 2021-06-14
TW202200148A (zh) 2022-01-01
JP2022046659A (ja) 2022-03-23
JO3618B1 (ar) 2020-08-27
TWI724993B (zh) 2021-04-21
MX379279B (es) 2025-03-11
US10085993B2 (en) 2018-10-02
EP3172209B1 (en) 2020-12-02
KR20230136693A (ko) 2023-09-26
IL250166B (en) 2021-01-31
EP3848376A1 (en) 2021-07-14
GT201700007A (es) 2018-12-18
US12208101B2 (en) 2025-01-28
FR22C1058I2 (fr) 2023-11-17
TW201613595A (en) 2016-04-16
AU2020200912A1 (en) 2020-02-27
PE20170523A1 (es) 2017-05-17
US20170231997A1 (en) 2017-08-17
EP3172209A1 (en) 2017-05-31
PT3172209T (pt) 2021-02-11
NO2022058I1 (no) 2022-12-16

Similar Documents

Publication Publication Date Title
NL301128I2 (nl) Risdiplam of een farmaceutisch aanvaardbaar zout daarvan
NL301344I2 (nl) lnavolisib of een farmaceutisch aanvaardbaar zout daarvan
NL301111I2 (nl) Entrectinib of een farmaceutisch aanvaardbaar zout daarvan
NL301286I2 (nl) Danicopan, of een farmaceutisch aanvaardbaar zout ervan
NL301208I2 (nl) capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301292I2 (nl) Iptacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301253I2 (nl) mavacamten of een farmaceutisch aanvaardbaar zout daarvan
NL301329I2 (nl) Lazertinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
FIC20265004I1 (fi) Sebetralstaatti tai sen farmaseuttisesti hyväksyttävä suola tai solvaatti
NO2022046I1 (no) Berotralstat and pharmaceutically acceptable salts thereof
NO2024007I1 (no) Elacestrant or a salt thereof
NO2022009I1 (no) Lumasiran, optionally in the form of a salt
NL301342I2 (nl) Elafibranor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2024009I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
IL256018A (en) Audible indicator
NL301061I2 (nl) givosiran of een farmaceutisch aanvaardbaar zout daarvan
DK3125836T3 (da) Vejrtrækningshjæpeapparat
NL301338I2 (nl) seladelpar of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder seladelpar-L-lysinedihydraat
HUE059927T2 (hu) Gombaölõ készítmények
LT3188717T (lt) Vaisto forma, apimanti daleles
HUE042087T2 (hu) Inhalátor
DK3199161T3 (da) Farmaceutisk præparat
NL301306I2 (nl) Delgocitinib of een farmaceutisch aanvaardbaar zout daarvan
LT3212237T (lt) Metotreksato vaistinė forma
EP3437644A4 (en) MEDICINE